# ğŸ“… Daily Report - 2026-01-31

> ä»Šæ—¥ç­›é€‰å‡º **53** æ¡å†…å®¹ï¼Œæ¥è‡ª **2** ä¸ªæ¥æº

<div class="powered-by-top">Powered by <a href="https://kyplus.de">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai">Claude</a></div>

---

## ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“

### ğŸ§¬ æ•°æ®å‰æ²¿

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
æ–°å‹mRNA-LNPç–«è‹—é¶å‘ç™Œç—‡-è§†ç½‘è†œæŠ—åŸPDE6Gï¼Œåœ¨å°é¼ æ¨¡å‹ä¸­å±•ç°å‡ºé’ˆå¯¹ä¹³è…ºç™Œçš„å¼ºå¤§æŠ—è‚¿ç˜¤å…ç–«æ½œåŠ›ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
*   **è‚¿ç˜¤å…ç–«ä¸æ²»ç–—**ï¼šæ¢ç´¢é¶å‘è‚¿ç˜¤ç‰¹å¼‚æ€§æŠ—åŸçš„ç–«è‹—ç­–ç•¥ï¼Œä»¥åŠå…ç–«ç»†èƒï¼ˆå¦‚CD8+ Tç»†èƒã€Kupfferç»†èƒï¼‰åœ¨è‚¿ç˜¤é€ƒé€¸ä¸­çš„ä½œç”¨æœºåˆ¶ï¼ˆå¦‚CUL5ã€VSIG4-CD5ç›¸äº’ä½œç”¨ï¼‰ã€‚
*   **ç™Œç—‡å‘ç”Ÿä¸å‘å±•æœºåˆ¶**ï¼šè§£æåŸºå› è°ƒæ§ï¼ˆå¦‚ACTBç”²åŸºåŒ–è°ƒæ§SMARCA4ã€RUVBL2è°ƒæ§çº¿ç²’ä½“è‡ªå™¬ï¼‰ã€ä¿¡å·é€šè·¯ï¼ˆå¦‚RAP1-MAPKã€PI3ï¤ï§æ¿€é…¶ï¼‰åœ¨å¤šç§ç™Œç—‡ï¼ˆå‰åˆ—è…ºç™Œã€ç»“ç›´è‚ ç™Œã€èƒ†å›Šç™Œï¼‰ä¸­çš„ä½œç”¨ã€‚
*   **å•ç»†èƒä¸ç©ºé—´ç»„å­¦**ï¼šåˆ©ç”¨å•ç»†èƒRNAæµ‹åºå’Œç©ºé—´è½¬å½•ç»„å­¦æŠ€æœ¯ï¼Œè§£æä¸åŒç»†èƒç±»å‹ï¼ˆå¦‚å°é¼ å¿ƒè„ã€æµ·é©¬å°èƒ¶è´¨ç»†èƒã€è‚ºéƒ¨å…ç–«ç»†èƒã€èƒ°è…ºå¯¼ç®¡è…ºç™Œå¾®ç¯å¢ƒï¼‰åœ¨ç”Ÿç†å’Œç—…ç†çŠ¶æ€ä¸‹çš„å¼‚è´¨æ€§å’ŒåŠŸèƒ½ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
*   **é«˜é€šé‡æµ‹åºæŠ€æœ¯çš„å¹¿æ³›åº”ç”¨**ï¼šåŒ…æ‹¬RNA-seqã€ChIP-seqã€ATAC-seqç­‰ï¼Œä¸ºåŸºå› è¡¨è¾¾ã€æŸ“è‰²è´¨å¯åŠæ€§åŠè›‹ç™½è´¨ç»“åˆä½ç‚¹ç ”ç©¶æä¾›äº†æœ‰åŠ›å·¥å…·ã€‚
*   **æ–°å‹ç–«è‹—æŠ€æœ¯**ï¼šmRNA-LNPç–«è‹—åœ¨æŠ—è‚¿ç˜¤å…ç–«ä¸­çš„åº”ç”¨ã€‚

### ğŸ§ª åšå®¢æ›´æ–°

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
ä¸€é¡¹20å¹´å‰çš„ä¹³è…ºç™Œç–«è‹—è¯•éªŒæ˜¾ç¤ºï¼Œæ‰€æœ‰å‚ä¸è€…å‡å®ç°é•¿æœŸç”Ÿå­˜ï¼Œä¸”å…ç–«ç³»ç»Ÿä¿ç•™äº†æŒä¹…è®°å¿†ï¼Œä¸ºè½¬ç§»æ€§ç–¾ç—…çš„é•¿æœŸæ²»ç–—å¸¦æ¥æ–°å¸Œæœ›ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- æ¢ç´¢æŠ—ä½“ç”Ÿæˆå…ç–«ç»†èƒï¼ˆå¦‚IgG1æµ†ç»†èƒï¼‰åœ¨å¢å¼ºç™Œç—‡å…ç–«æ²»ç–—ä¸­çš„ä½œç”¨æœºåˆ¶ã€‚
- æ­ç¤ºIDHçªå˜èƒ¶è´¨ç˜¤åœ¨æ—©æœŸé˜¶æ®µçš„å‘ç”Ÿå‘å±•è¿‡ç¨‹ï¼Œä¸ºç–¾ç—…çš„æ—©æœŸæ£€æµ‹å’Œå¹²é¢„æä¾›çº¿ç´¢ã€‚
- å¼€å‘æ–°å‹â€œç‰¹æ´›ä¼Šæœ¨é©¬â€ç–—æ³•ï¼Œåˆ©ç”¨è‚¿ç˜¤è‡ªèº«é˜²å¾¡æœºåˆ¶å¯¹æŠ—è½¬ç§»æ€§ç™Œç—‡ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- scRNA-seqæŠ€æœ¯ç»“åˆå…ç–«åˆ†æï¼Œæ­ç¤ºäº†ç‰¹å®šå…ç–«ç»†èƒåœ¨å…ç–«æ²»ç–—ä¸­çš„å…³é”®ä½œç”¨ã€‚
- é•¿æœŸéšè®¿ç ”ç©¶ï¼Œè¯å®äº†ç™Œç—‡ç–«è‹—çš„æŒä¹…ç–—æ•ˆåŠå…ç–«è®°å¿†çš„å½¢æˆã€‚

---

## ğŸ“š åˆ†ç±»æµè§ˆ

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (48æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰

**1.** â­ **GSE317984 é¶å‘ç™Œè§†ç½‘è†œæŠ—åŸPDE6Gçš„mRNA-LNPç–«è‹—å¯è¯±å¯¼é’ˆå¯¹ä¹³è…ºç™Œçš„å¼ºæ•ˆæŠ—è‚¿ç˜¤å…ç–«**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€immunityã€vaccineã€antigen
- ğŸ“ **æè¿°**ï¼šContributors : Yue Zhao ; Yichun Pan ; Wei Zhang ; Zhao ZuoSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe development of effective mRNA vaccines for breast cancer has been constrained by the lack of highly immunogenic and tumor-specific antigens. Here, we identify PDE6G, an immune-privileged retina-enriched antigen aberrantly overexpressed in breast tumors, and develop a PDE6G mRNA-LNP vaccine. Vaccination elicited robust CD8+ T cell responses, promoted clonal expansion of effector and IFN-competent T cell subsets, and suppressed tumor growth without detectable toxicity. Single-cell RNA sequencing (scRNA-seq) revealed that vaccination of PDE6G mRNA-LNP reshapes the tumor immune microenvironment (TIME) by expanding antigen-presenting Cd74+ tumor-associated macrophages (TAMs) while reducing immunosuppressive Maf+ macrophages, and enhancing crosstalk between macrophages and CD8+ T cells. Moreover, combining PDE6G mRNA-LNP with PD-1 blockade further improved anti-tumor efficacy. These findings establish cancer-retina antigens as promising vaccine targets and demonstrate that PDE6G mRNA-LNP coordinates adaptive immunity and tumor microenvironment remodeling, providing a safe and potent strategy for breast cancer immunotherapy.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317984)

**2.** â­ **GSE287028 PDGFC é€šè¿‡è‡ªåˆ†æ³Œæ¿€æ´» RAP1-MAPK é€šè·¯ä¿ƒè¿›å‰åˆ—è…ºç™Œäº§ç”Ÿæ©æ‰å¢èƒºè€è¯æ€§**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€resistanceã€pathway
- ğŸ“ **æè¿°**ï¼šContributors : Bingqian Deng ; Saipeng Chen ; Dan Zhong ; Guojing SongSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensProstate cancer (PCa) is a highly heterogeneous malignant tumor within the male genitourinary system, characterized by its invasive and metastatic potential. Although the second-generation androgen receptor (AR) antagonist enzalutamide has shown therapeutic efficacy in PCa patients, enzalutamide resistance (EnzaR) will be inevitably develops and the underlying mechanisms are not fully understood. In this study, we confirmed that the expression of Platelet-Derived Growth Factor C (PDGFC) elevated in EnzaR PCa and promoted the proliferation of PCa in vitro and in vivo. Silencing PDGFC in EnzaR cells notably enhances the sensitivity of EnzaR PCa cells to enzalutamide, thereby inhibiting the progressive of PCa. Mechanistically, overexpressed PDGFC activates the PDGFR-RAP1-MAPK signaling cascade in an autocrine fashion within EnzaR cells. PDGFR inhibitors alone or combined with enzalutamide significantly suppressed the progression of EnzaR PCa xenografts. Additionally, we demonstrated that the transcription factor STAT4 binds to a specific DNA sequence in the PDGFC promoter region, which is essential for PDGFC upregulation. Collectively, our results confirmed the pivotal role of PDGFC in PCa cells developing resistant to enzalutamide therapy, suggesting that targeting PDGFC may serve as a promising therapeutic strategy for EnzaR PCa.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287028)

**3.** **GSE317951 PI3Î´Î³æ¿€é…¶å’ŒIFN-Î³é€šè·¯ï¼Œæ˜¯åœ¨ä¸€é¡¹æ— åæ¿€é…¶è¯ç‰©ç­›é€‰ä¸­å‘ç°çš„ï¼Œæ˜¯ç»†èƒå› å­é‡Šæ”¾ç»¼åˆå¾çš„å…³é”®ä»‹è´¨ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcytokineã€kinase
- ğŸ“ **æè¿°**ï¼šContributors : Amatya Parmeshwar ; O'Neal Julie ; Jayasinghe Reyka ; DiPersio JohnSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensChimeric Antigen Receptor T (CAR-T) cell therapy can induce cytokine release syndrome (CRS), which ranges clinically from mild to life-threatening, and is universally characterized by elevation of multiple cytokines, including IL-6. To clarify mechanisms underlying CRS and identify potential new therapeutic agents, we screened a protein kinase inhibitor library using an in vitro model system where CART19 cells were co-cultured with CD19+ tumor target cells and cytokine-primed myeloid cells (pMC), and secreted IL-6 levels serving as the CRS readout. We identified duvelisib, a dual PI3Kdg inhibitor, which blocked pMC IL-6 secretion in in vitro and in vivo without negative impact on CART19 cell function. Immunophenotyping showed increased activation markers on CART19 cells CD137+(4-1BB); CD279+ (PD-1) and pMC cells (CD83+CD86+) when cultured with tumor target cells compared to cultures without target cells; these activation phenotypes were reduced in the presence of duvelisib. Single-cell RNA sequencing analyses identified four transcriptional clusters of pMCs. Among these, the activated pMC1 subset was the primary source of IL-6 expression, which was effectively reduced by duvelisib and by ruxolitinib, a JAK1/2 kinase inhibitor known to block CRS. Transcriptionally, IFNG expression in CART19 cells was significantly downregulated in the presence of duvelisib and ruxolitinib, and cell-cell communication between CART19 cells and pMCs suggests different mechanisms of action for the two inhibitors. Finally, pMC IL-6 production was significantly reduced by CRISPR/Cas9 deletion of IFNG in CART19 cells, the IFN-g receptor in pMC, or treatment with duvelisib which blocks both IFN-g production by CART19 and IFN-g receptor signaling. Our studies suggest that targeting PI3dg and IFN-g signaling pathways reduce CRS without altering CAR-T cell function.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317951)

**4.** **GSE308376 ACTBç”²åŸºåŒ–è°ƒæ§SMARCA4åŸºå› ç»„å ä½ï¼Œä»è€Œä¿ƒè¿›ç¿»è¯‘å¹¶é™ä½ç»“ç›´è‚ ç™Œç»†èƒçš„é»é™„æ€§**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€methylation
- ğŸ“ **æè¿°**ï¼šContributor : Elina Abeav-SchneidermanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensACTB is a cytoskeletal protein involved in intracellular trafficking. In recent years, it has become evident that, in addition to its established roles in these compartments, ACTB also participates in the regulation of transcription. However, the molecular mechanisms underlying this function remain poorly understood. The methyltransferase SETD3 has previously been shown to methylate ACTB at H73, thereby regulating ACTB polymerization and smooth muscle contraction. Here, we show that the genomic distribution of ACTB is SETD3-dependent and that this regulation modulates the transcription of genes involved in cell adhesion and mRNA translation in colorectal cancer cells. Proteomic analyses reveal that ACTB and SETD3 interact with multiple large protein complexes, including complexes associated with transcriptional regulation. Specifically, we demonstrate that SETD3-mediated ACTB methylation is required for the co-localization of SMARCA4, a subunit of the SWI/SNF BAF complex, at specific genomic loci. Genomic analyses further show that this co-localization enables the coordinated occupancy of SMARCA4 and H73-methylated ACTB at genes involved in cell adhesion and mRNA translation. Finally, phenotypic assays confirm these regulatory effects. Together, these findings uncover a new mechanistic layer of selective transcriptional regulation mediated by an ACTBâ€“SETD3â€“SMARCA4 axis in colorectal cancer cells.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308376)

**5.** **GSE308375 ACTBç”²åŸºåŒ–è°ƒæ§SMARCA4åŸºå› ç»„å ä½ï¼Œä»è€Œä¿ƒè¿›ç¿»è¯‘å¹¶é™ä½ç»“ç›´è‚ ç™Œç»†èƒçš„é»é™„æ€§**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€methylation
- ğŸ“ **æè¿°**ï¼šContributor : Abeav-Schneiderman ElinaSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensACTB is a cytoskeletal protein involved in intracellular trafficking. In recent years, it has become evident that, in addition to its established roles in these compartments, ACTB also participates in the regulation of transcription. However, the molecular mechanisms underlying this function remain poorly understood. The methyltransferase SETD3 has previously been shown to methylate ACTB at H73, thereby regulating ACTB polymerization and smooth muscle contraction. Here, we show that the genomic distribution of ACTB is SETD3-dependent and that this regulation modulates the transcription of genes involved in cell adhesion and mRNA translation in colorectal cancer cells. Proteomic analyses reveal that ACTB and SETD3 interact with multiple large protein complexes, including complexes associated with transcriptional regulation. Specifically, we demonstrate that SETD3-mediated ACTB methylation is required for the co-localization of SMARCA4, a subunit of the SWI/SNF BAF complex, at specific genomic loci. Genomic analyses further show that this co-localization enables the coordinated occupancy of SMARCA4 and H73-methylated ACTB at genes involved in cell adhesion and mRNA translation. Finally, phenotypic assays confirm these regulatory effects. Together, these findings uncover a new mechanistic layer of selective transcriptional regulation mediated by an ACTBâ€“SETD3â€“SMARCA4 axis in colorectal cancer cells.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308375)

**6.** **GSE279149 CUL5 E3æ³›ç´ è¿æ¥é…¶é€šè¿‡æŠ‘åˆ¶è‡ªå™¬æ¥è°ƒèŠ‚è†€èƒ±ç™Œç»†èƒé€ƒé¿CD8+ Tç»†èƒä»‹å¯¼çš„æ€ä¼¤ä½œç”¨**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€T cell
- ğŸ“ **æè¿°**ï¼šContributors : Xincheng Gao ; Hui Zhang ; Guosong JiangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCD8+ T cells are capable of specifically targeting and eliminating malignant tumor cells, but tumor cells can develop resistance mechanisms to escape CD8+ T cell-mediated killing. Here, we performed a whole genome CRISPR-Cas9 knockout screen under CD8+ T cells pressure and identified the E3 ubiquitin ligase CUL5 as an essential factor required for escaping CD8+ T cells killing in bladder cancer cells. We found that CUL5 knockout promoted the sensitivity of bladder cancer cells to CD8+ T cell-mediated killing both in vivo and in vitro. Mechanistically, CUL5 loss reduced the ubiquitination of PTBP1, which regulated alternative splicing of RUBCN pre-mRNA and led to an increase in the levels of the RUBCN-S isoform, thereby preventing immune evasion of bladder cancer cells by inhibiting autophagy. Importantly, CUL5 knockout significantly enhanced the efficacy of anti-PD-1 immunotherapy in a xenograft model. Collectively, these findings reveal a novel mechanism of bladder cancer immune evasion, providing potential targets for cancer immunotherapy.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279149)

**7.** **GSE317479 æ­£å¸¸è„‚è‚ªé¥®é£Ÿå’Œé«˜è„‚è‚ªé¥®é£Ÿæ¡ä»¶ä¸‹å°é¼ å¿ƒè„çš„å•ç»†èƒRNAæµ‹åº**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šsequencingã€single-cell
- ğŸ“ **æè¿°**ï¼šContributors : Junichi Sadoshima ; Shin-ichi Oka ; Eun-Ah Sung ; Alexander Lemenze ; Mainul HoqueSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusTo investigate transcriptional changes in the heart induced by diet, we performed single-cell RNA sequencing on pooled mouse hearts from normal fat diet (NFD, 10% kcal fat) and high fat diet (HFD, 60% kcal fat) groups using the Parse Biosciences Evercode WT Mini v3 kit.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317479)

**8.** **GSE307881 ä½“å¤–å—ç²¾è¯±å¯¼é›Œæ€§å°é¼ åä»£è¿‡æ—©å‡ºç°ç”Ÿæ®–è¡°è€å’Œå¤šä»£è¡¨è§‚é—ä¼ æ”¹å˜**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šagingã€epigenetic
- ğŸ“ **æè¿°**ï¼šContributors : Eric A Rhon-Calderon ; Cassidy N Hemphill ; Alexandra J Savage ; Christopher J Krapp ; Zhengfeng Liu ; Laren Riesche ; Richard M Schultz ; Marisa S BartolomeiSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusIn vitro fertilization (IVF) is an assisted reproductive technology that has enabled millions of births. Although considered safe, emerging evidence suggests that IVF may have long-term health adverse outcomes in offspring, though its impact on female reproduction, especially on reproductive aging is largely unknown. Here, we use a mouse model to investigate how IVF influences female reproductive and transgenerational health outcomes. We assessed IVF-conceived fetal (E18.5) and adult (12-week and 39-week) female offspring, identifying alterations in ovarian-to-body weight ratios, ovarian morphology, serum sex hormone levels, and transcriptomic and DNA methylation profiles in ovaries, oocytes, and cumulus cells, consistent with biomarkers of accelerated reproductive aging. The offspring of IVF females and wild-type males exhibited altered fetal-to-placental weight ratios, placental morphology, and dysregulated placental gene expression. At 12-weeks-of-age, offspring showed increased body weight, disrupted lipid and glucose metabolism, and transcriptomic and epigenetic changes in liver and reproductive organs. Our results highlight the need for deeper mechanistic understanding of assisted reproductionâ€™s long-term and multigenerational impacts on female reproductive health.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307881)

**9.** **GSE304224 PU.1 æ¿€æ´»çš„åŸºå› ç»„åŒºåŸŸå®šä¹‰äº†ä»¥å…ç–«å¤±è°ƒå’Œç–¾ç—…è¿›å±•ä¸ºç‰¹å¾çš„ä½é£é™© MDS äºšç¾¤ [MDS-L ChIP-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šimmuneã€ChIP-seq
- ğŸ“ **æè¿°**ï¼šContributors : Veronica Vallelonga ; Francesco Gandolfi ; Matteo Zampini ; Elena Riva ; Giulia Maggioni ; Denise Ventura ; Elena Saba ; Alberto Termanini ; Sara Polletti ; Elena Prosperini ; Laura Crisafulli ; Alessia Campagna ; Ivan Ferrari ; Nicole Pinocchio ; Gabriele Todisco ; Michela Calvi ; Clara Di Vito ; Domenico Mavilio ; Francesca Ficara ; Matteo Giovanni Della Porta ; Serena GhislettiSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensMyelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms with an increased risk of progression to secondary acute myeloid leukemia (sAML). This study investigates the genomic correlates of disease progression in MDS by profiling active genomic regulatory regions and their transcriptional impact through H3K27ac ChIP-seq and RNA-seq analysis on CD34+ bone marrow progenitors cells isolated from a prospective cohort of 86 and 357 patients, respectively. Our analysis revealed distinct patterns of genomic region activation and transcriptional regulation across different disease stages (low-risk MDS, high-risk MDS and sAML). Unexpectedly, unsupervised clustering revealed a subset of low-risk MDS patients displaying regulatory and transcriptional profiles similar to those of high-risk MDS and sAML, highlighting early molecular events that may predispose patients to disease progression. This subset is characterized by PU.1 genomic occupancy in regions linked to immune and inflammatory responses, increased T-cell and NK activation, and a higher frequency of SRSF2 mutations. Clinically, patients in this group exhibit greater susceptibility to infections and cardiovascular events, along with an elevated risk of disease progression, resulting in a significantly reduced overall survival. Functional studies demonstrate that PU.1 inhibition suppresses MDS cell proliferation and clonogenicity, as impaired PU.1 binding inhibits the activation of key transcriptional programs involved in disease advancement. Collectively, these findings identify epigenetic factors that predispose low-risk MDS patients to progression into high-risk MDS and, ultimately, sAML. Moreover, they provide proof of concept for targeting PU.1 as a potential strategy to prevent disease progression in low-risk MDS.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304224)

**10.** **GSE303742 PU.1 æ¿€æ´»çš„åŸºå› ç»„åŒºåŸŸå®šä¹‰äº†ä»¥å…ç–«å¤±è°ƒå’Œç–¾ç—…è¿›å±•ä¸ºç‰¹å¾çš„ä½é£é™© MDS äºšç¾¤ [MDS-L RNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šimmuneã€RNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Veronica Vallelonga ; Francesco Gandolfi ; Matteo Zampini ; Elena Riva ; Giulia Maggioni ; Denise Ventura ; Elena Saba ; Alberto Termanini ; Sara Polletti ; Elena Prosperini ; Laura Crisafulli ; Alessia Campagna ; Ivan Ferrari ; Nicole Pinocchio ; Gabriele Todisco ; Silvia Pedretti ; Michela Calvi ; Clara Di Vito ; Domenico Mavilio ; Francesca Ficara ; Matteo Giovanni Della Porta ; Serena GhislettiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMyelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms with an increased risk of progression to secondary acute myeloid leukemia (sAML). This study investigates the genomic correlates of disease progression in MDS by profiling active genomic regulatory regions and their transcriptional impact through H3K27ac ChIP-seq and RNA-seq analysis on CD34+ bone marrow progenitors cells isolated from a prospective cohort of 86 and 357 patients, respectively. Our analysis revealed distinct patterns of genomic region activation and transcriptional regulation across different disease stages (low-risk MDS, high-risk MDS and sAML). Unexpectedly, unsupervised clustering revealed a subset of low-risk MDS patients displaying regulatory and transcriptional profiles similar to those of high-risk MDS and sAML, highlighting early molecular events that may predispose patients to disease progression. This subset is characterized by PU.1 genomic occupancy in regions linked to immune and inflammatory responses, increased T-cell and NK activation, and a higher frequency of SRSF2 mutations. Clinically, patients in this group exhibit greater susceptibility to infections and cardiovascular events, along with an elevated risk of disease progression, resulting in a significantly reduced overall survival. Functional studies demonstrate that PU.1 inhibition suppresses MDS cell proliferation and clonogenicity, as impaired PU.1 binding inhibits the activation of key transcriptional programs involved in disease advancement. Collectively, these findings identify epigenetic factors that predispose low-risk MDS patients to progression into high-risk MDS and, ultimately, sAML.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303742)

> ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 38 æ¡å†…å®¹ï¼Œè¯¦è§ [æ–‡æœ«](#æ›´å¤š-æ•°æ®å‰æ²¿)

</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (5æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨5æ¡ï¼‰

**1.** â­ **å•ç»†èƒRNAæµ‹åºæ­ç¤ºäº†èƒ½å¤Ÿå¸®åŠ©å¡‘é€ ç™Œç—‡å…ç–«ç–—æ³•çš„æŠ—ä½“äº§ç”Ÿå…ç–«ç»†èƒã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€immuneã€antibodyã€regex:immuno(logy|therapy|suppression)ã€scRNA
- ğŸ“ **æè¿°**ï¼šRNA sequencing and immune profiling reveal that IgG1-producing plasma cells support effective PD-1 immunotherapy responses by coordinating antibody and T cell activity in cancer patients...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/scrna-seq-reveals-antibody-producing-immune-cells-that-can-help-shape-cancer-immunotherapy/)

**2.** **ä¸€ç§å·²æœ‰20å¹´å†å²çš„ç™Œç—‡ç–«è‹—æˆ–è®¸æ˜¯å»¶é•¿ç™Œç—‡æ‚£è€…ç”Ÿå­˜æœŸçš„å…³é”®ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€vaccine
- ğŸ“ **æè¿°**ï¼šTwo decades after a breast cancer vaccine trial, every participant is still aliveâ€”an astonishing result for metastatic disease. Scientists found their immune systems retained long-lasting memory cells primed to recognize cancer. By enhancing a key immune signal called CD27, researchers dramatically improved tumor elimination in lab studies. The findings suggest cancer vaccines may have been missing a crucial ingredient all along.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2026/01/260128075345.htm)

**3.** **é•¿æœŸé¥®é…’ä¸ç›´è‚ ç™Œå‘ç—…ç‡æ€¥å‰§ä¸Šå‡æœ‰å…³**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancer
- ğŸ“ **æè¿°**ï¼šDrinking heavily over many years is linked to a higher risk of colorectal cancer, especially rectal cancer, according to new research tracking U.S. adults for two decades. People who drank heavily throughout adulthood faced sharply higher risks than light drinkers. Former drinkers did not show increased cancer risk and had fewer precancerous tumors. The results suggest that quitting alcohol may help lower long-term cancer risk.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2026/01/260128230514.htm)

**4.** **è„‘ç™Œå¯èƒ½åœ¨åŒ»ç”Ÿå‘ç°ä¹‹å‰æ•°å¹´å°±å·²ç»å­˜åœ¨ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancer
- ğŸ“ **æè¿°**ï¼šScientists in South Korea have discovered that one of the most common malignant brain tumors in young adults may begin years before a tumor can be seen. IDH-mutant glioma, long treated by removing visible tumor tissue, actually starts when normal-looking brain cells quietly acquire a cancer-linked mutation and spread through the brainâ€™s cortex. Using advanced genetic mapping and animal models, researchers traced the cancerâ€™s true origin to glial progenitor cells that appear healthy at first.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2026/01/260128075350.htm)

**5.** **ä¸€ç§ç‰¹æ´›ä¼Šæœ¨é©¬å¼ç™Œç—‡ç–—æ³•æ˜¾ç¤ºå‡ºæƒŠäººçš„æ•ˆæœ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancer
- ğŸ“ **æè¿°**ï¼šScientists at Mount Sinai have unveiled a bold new way to fight metastatic cancer by turning the tumorâ€™s own defenses against it. Instead of attacking cancer cells head-on, the experimental immunotherapy targets macrophagesâ€”immune cells that tumors hijack to shield themselves from attack. By eliminating or reprogramming these â€œbodyguards,â€ the treatment cracks open the tumorâ€™s protective barrier and allows the immune system to flood in and destroy the cancer.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2026/01/260128075332.htm)


</div>

</details>

## ğŸ“Š å…³é”®è¯ç»Ÿè®¡

| å…³é”®è¯ | å‡ºç°æ¬¡æ•° |
|--------|----------|
| cancer | 16 |
| immune | 8 |
| single-cell | 5 |
| RNA-seq | 5 |
| tumor | 5 |
| sequencing | 4 |
| histone | 4 |
| transcriptome | 3 |
| pathway | 3 |
| methylation | 3 |
| T cell | 3 |
| ChIP-seq | 3 |
| ATAC-seq | 2 |
| vaccine | 2 |
| resistance | 2 |
| antibody | 1 |
| regex:immuno(logy|therapy|suppression) | 1 |
| scRNA | 1 |
| cytokine | 1 |
| kinase | 1 |

---

## ğŸ“ æ›´å¤šå†…å®¹

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (38æ¡)</summary>

<div class="details-content" markdown="1">

- [GSE298019 PU.1 æ¿€æ´»çš„åŸºå› ç»„åŒºåŸŸå®šä¹‰äº†ä»¥å…ç–«å¤±è°ƒå’Œç–¾ç—…è¿›å±•ä¸ºç‰¹å¾çš„ä½é£é™© MDS äºšç¾¤ [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298019)
- [GSE297914 PU.1 æ¿€æ´»çš„åŸºå› ç»„åŒºåŸŸå®šä¹‰äº†ä»¥å…ç–«å¤±è°ƒå’Œç–¾ç—…è¿›å±•ä¸ºç‰¹å¾çš„ä½é£é™© MDS äºšç¾¤ [ChIP-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297914)
- [GSE317927 èƒå„¿ç”Ÿé•¿å—é™å°é¼ æµ·é©¬å°èƒ¶è´¨ç»†èƒçš„å•ç»†èƒRNAæµ‹åº](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317927)
- [GSE317548 RUVBL2 è½¬å½•è°ƒæ§èƒ†å›Šç™Œç»†èƒä¸­çš„çº¿ç²’ä½“è‡ªå™¬é€šè·¯](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317548)
- [GSE317515 åº“æ™®å¼—ç»†èƒé€šè¿‡ VSIG4-CD5 ç›¸äº’ä½œç”¨æ ¡å‡† T ç»†èƒååº”ä¿ƒè¿›è‚¿ç˜¤é€ƒé€¸ [TCR-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317515)
- [GSE317513 Kupffer ç»†èƒé€šè¿‡ VSIG4-CD5 ç›¸äº’ä½œç”¨æ ¡å‡† T ç»†èƒååº”ä¿ƒè¿›è‚¿ç˜¤é€ƒé€¸ [bulkRNA]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317513)
- [GSE317400 äººç±»åµå·¢ç™Œä¸­CLDN6é˜³æ€§å®æ€§åŒºåŸŸå’Œå°ç°‡åŒºåŸŸçš„ç©ºé—´è½¬å½•ç»„åˆ†æ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317400)
- [GSE310853 CRAMP1 å¯¹ç»„è›‹ç™½åŸºå› åº§å†…ç»„è›‹ç™½ H1 è¡¨è¾¾çš„ç‹¬ç‰¹æ§åˆ¶ [ChIP-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310853)
- [GSE310852 CRAMP1 å¯¹ç»„è›‹ç™½åŸºå› åº§å†…ç»„è›‹ç™½ H1 è¡¨è¾¾çš„ç‹¬ç‰¹æ§åˆ¶ [ATAC-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310852)
- [GSE288459 è‚ºå…ç–«ç»†èƒç¾¤ä¸­ç»“èŠ‚ç—…çš„å•ç»†èƒè½¬å½•ç»„ç‰¹å¾](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288459)
- [GSE288067 å•ç»†èƒ RNA æµ‹åºç»“åˆå¤šé‡å…ç–«è§å…‰æ¢é’ˆæ­ç¤º MFAP5+ æˆçº¤ç»´ç»†èƒåœ¨èƒ°è…ºå¯¼ç®¡è…ºç™Œå¾®ç¯å¢ƒä¸­çš„ä½œç”¨ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288067)
- [GSE317696 äººç±»æ€§è…ºç»„ç»‡è½¬å½•ç»„åˆ†æï¼ˆå‘è¡¨äºã€Šæ€§åˆ«å‘è‚²å·®å¼‚ã€‹æœŸåˆŠï¼‰](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317696)
- [GSE312455 é…¿é…’é…µæ¯ä¸åŒèŒæ ªä¸­ä¿å®ˆçš„ HOG é€šè·¯è¡¨ç°å‡ºä»¤äººæƒŠè®¶çš„è°ƒæ§å¯å¡‘æ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312455)
- [GSE317728 æˆå¹´å°é¼ èƒŒæ ¹ç¥ç»èŠ‚èƒ¶è´¨ç»†èƒå•ç»†èƒè½¬å½•ç»„å›¾è°±é‰´å®šå‡ºå¤šèƒ½ç¥–ç»†èƒ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317728)
- [GSE301514 ID3 ç¼ºé™·æ”¹å˜ DSB ä½ç‚¹çš„æŸ“è‰²è´¨å¯åŠæ€§å¹¶å¢å¼ºå¯¹ HDAC æŠ‘åˆ¶çš„æ•æ„Ÿæ€§ [ATAC-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301514)
- [GSE301513 ID3 ç¼ºé™·æ”¹å˜ DSB ä½ç‚¹çš„æŸ“è‰²è´¨å¯åŠæ€§å¹¶å¢å¼ºå¯¹ HDAC æŠ‘åˆ¶çš„æ•æ„Ÿæ€§ [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301513)
- [GSE298020 PU.1 æ¿€æ´»çš„åŸºå› ç»„åŒºåŸŸå®šä¹‰äº†ä»¥å…ç–«å¤±è°ƒå’Œç–¾ç—…è¿›å±•ä¸ºç‰¹å¾çš„ä½é£é™© MDS äºšç»„ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298020)
- [GSE297740 å„¿ç«¥Bç»†èƒå°è®°ä¼šæŸå®³é’ˆå¯¹è¡€å‡ç´ èŒçš„æŠ—ä½“](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297740)
- [GSE289389 ç ”ç©¶æ˜¾ç¤ºï¼Œç³»ç»Ÿæ€§çº¢æ–‘ç‹¼ç–®çš„çš®è‚¤å…‰ååº”ä»¥è¡¨çš®ç‚ç—‡å¤±è°ƒå’Œç‚ç—‡æ€§é«“ç³»ç»†èƒæµ¸æ¶¦ä¸ºç‰¹å¾ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289389)
- [GSE301229 è½¬è°·æ°¨é…°èƒºé…¶ 2 åœ¨è„“æ¯’ç—‡å·¨å™¬ç»†èƒæ´»åŒ–è¿‡ç¨‹ä¸­è°ƒèŠ‚æ³¢å½¢è›‹ç™½ä¾èµ–æ€§è›‹ç™½è´¨ç¨³æ€](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301229)
- [GSE279695 äººç±»è¯±å¯¼å¤šèƒ½å¹²ç»†èƒæ¥æºçš„å¿ƒè‚Œç»†èƒå’Œç•¸èƒç˜¤ç§»æ¤åçš„ä»£è°¢å˜åŒ–](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279695)
- [GSE231494 çŒªè‚ºå¯¹èƒ¸è†œè‚ºç‚æ”¾çº¿æ†èŒååº”çš„å•ç»†èƒå›¾è°±](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE231494)
- [GSE317999 å®«å†…ç”Ÿé•¿å—é™å¯¹æµ·é©¬å°èƒ¶è´¨ç»†èƒè½¬å½•ç»„çš„å½±å“](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317999)
- [GSE317924 å®«å†…ç”Ÿé•¿å—é™å¯¹æµ·é©¬å°èƒ¶è´¨ç»†èƒDNAç”²åŸºåŒ–çš„å½±å“](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317924)
- [GSE317483 ç”¨é’™è°ƒç£·é…¸é…¶æŠ‘åˆ¶å‰‚å¤„ç†çš„æ°¸ç”ŸåŒ–äººè¶³ç»†èƒçš„ RNA æµ‹åº](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317483)
- [GSE316921 æ•²ä½è‚å†…èƒ†ç®¡ç™Œï¼ˆICCï¼‰ç™Œç›¸å…³æˆçº¤ç»´ç»†èƒï¼ˆCAFsï¼‰ä¸­SLC2A1å¯¹æ­£å¸¸å’Œç¼ºæ°§æ¡ä»¶ä¸‹å†…çš®ç»†èƒå‡ºèŠ½çš„å½±å“](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316921)
- [GSE315861 é¶å‘å…ˆå¤©å…ç–«æŠ‘åˆ¶ç–—æ³•ä¸æŠ—ç”Ÿç´ æ²»ç–—å¤å‘æ€§æ€¥æ€§è†€èƒ±ç‚çš„æ¯”è¾ƒ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315861)
- [GSE315735 NIH:OVCAR-3å¼‚ç§ç§»æ¤ç˜¤ä¸­åŸºå› è¡¨è¾¾æƒ…å†µï¼ˆè½½ä½“æˆ–å¡é“‚æ²»ç–—ï¼‰](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315735)
- [GSE315733 NIH:OVCAR-3 å¼‚ç§ç§»æ¤ç˜¤ä¸­åŸºå› è¡¨è¾¾ï¼ˆè½½ä½“æˆ–å¡é“‚æ²»ç–—ï¼‰[è¿›å±•]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315733)
- [GSE314786 æ­å¼€ WRN è§£æ—‹é…¶çš„å¥¥ç§˜ï¼šç»“æ„è§£ææ­ç¤ºæ„è±¡çŠ¶æ€åŠ MSI-H ç™Œç—‡è¯ç‰©ç ”å‘çš„æœºé‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314786)
- [GSE312730 Simtuzumab å¯å‡å¼± Loxl2 ä»‹å¯¼çš„ç»†èƒå¤–åŸºè´¨é‡å¡‘ï¼Œå¹¶åœ¨ LMNA çªå˜è¯±å¯¼çš„æ‰©å¼ å‹å¿ƒè‚Œç—…ä¸­ä¿æŠ¤å¿ƒè„åŠŸèƒ½](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312730)
- [GSE311986 ä¸€ç§åŸºäºCasRxçš„æ–°æ–¹æ³•é‰´å®šå‡ºTRA2Bæ˜¯æ™šæœŸå‰åˆ—è…ºç™Œä¸­AR-V7çš„å…³é”®å‰ªæ¥è°ƒèŠ‚å› å­](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311986)
- [GSE310913 CRAMP1 å¯¹ç»„è›‹ç™½åŸºå› åº§å†…ç»„è›‹ç™½ H1 è¡¨è¾¾çš„ç‹¬ç‰¹è°ƒæ§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310913)
- [GSE310855 CRAMP1 å¯¹ç»„è›‹ç™½åŸºå› åº§å†…ç»„è›‹ç™½ H1 è¡¨è¾¾çš„ç‹¬ç‰¹æ§åˆ¶ [BiSulfite-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310855)
- [GSE310854 RNA-seq åˆ†æ CRAMP1 è°ƒæ§çš„åŸºå› è¡¨è¾¾](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310854)
- [GSE310036 piR-37524æŠ‘åˆ¶åHCT116å’ŒHT29ç»“ç›´è‚ ç™Œç»†èƒçš„è½¬å½•ç»„åˆ†æ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310036)
- [GSE286977 é¸¡ç›²è‚ ç»„ç»‡mRNAé“¾ç‰¹å¼‚æ€§æµ‹åº](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286977)
- [GSE286402 ç ”ç©¶å‘ç°ï¼ŒBRAFæŠ‘åˆ¶å‰‚è€è¯æ€§å¯¼è‡´é»‘è‰²ç´ ç˜¤å¯¹Chk1æŠ‘åˆ¶å‰‚æ•æ„Ÿã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286402)

</div>

</details>

---

*ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-01-30 21:46*  
*ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ*